AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00002514
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002514
Drug: imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00002514
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002514
Drug: thioguanine
RxNorm normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002514
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03078738
Drug: OMT-28
RxNorm normalized name: Omtryg
DrugBank: Omega-3-acid ethyl esters (DB09539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMT-28 is a fully synthetic small molecule that belongs to the family of 17,18-epoxyeicosatetraenoic acids (17,18-EEQ) analogs, a natural metabolite of the omega-3 fatty acid eicosapentaenoic acid (EPA).
Trial: NCT01547312
Drug: Peg-Interferon
RxNorm normalized name: PEG-Interferon alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polyethyleneglycolated Interferon alfa-2b at 1.5 ug/kg/week, administered subcutaneously, once a week, over the entire course of the study.
Trial: NCT01547312
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin, 600-1400 mg administered orally, twice daily, over the entire course of the study.
Trial: NCT01547312
Drug: 800 mg Grazoprevir
DrugBank: Grazoprevir (DB11575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 800 mg Grazoprevir administered orally, once per day, for 7 consecutive days.
Trial: NCT01547312
Drug: 100 mg Grazoprevir
RxNorm normalized name: grazoprevir 100 MG
DrugBank: Grazoprevir (DB11575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg Grazoprevir administered orally, once per day, for 7 consecutive days.
Trial: NCT00096018
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00096018
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Orally
Trial: NCT00278330
Drug: alvocidib
RxNorm normalized name: Alvocidib
DrugBank: Alvocidib (DB03496)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by infusion
Trial: NCT00278330
Drug: vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00386555
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00386555
Drug: CP-868,596 + docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00386555
Drug: AG-013736 + docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00386555
Drug: CP-868,596 + AG-013736 + docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01719003
Drug: Metformin 500 mg bid
RxNorm normalized name: metformin 500 MG
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 500 mg twice daily
Trial: NCT01719003
Drug: Metformin 1000 mg bid
RxNorm normalized name: metformin 1000 MG
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 1000 mg twice daily
Trial: NCT01719003
Drug: Empagliflozin low dose qd
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin low dose once daily
Trial: NCT01719003
Drug: Empagliflozin high dose qd
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin high dose once daily
Trial: NCT01719003
Drug: Empagliflozin low dose bid
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin low dose split twice daily
Trial: NCT01719003
Drug: Empagliflozin high dose bid
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin high dose split twice daily
Trial: NCT01260025
Drug: PEDylated Recombinant Human Endostatin
RxNorm normalized name: Recombinant human endostatin
DrugBank: Endostatin (DB06423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial dose of PEDylated Recombinant Human Endostatin (M2ES) will be 7.5mg/m2.Dose Escalation to a next higher level will occur when 3 patients in the same dose level complete 28 days of continuous treatment without experiencing a dose-limiting toxicity.
Trial: NCT03545997
Drug: Montelukast 10mg
RxNorm normalized name: montelukast 10 MG
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The capsules will be presented in box of 95 capsules packaged in unit blister
Trial: NCT01616485
Drug: TA-1790
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 TA-1790 100 mg capsules
Trial: NCT01342549
Drug: Valproate
RxNorm normalized name: Valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250mg per day 30 minutes after a meal. Dosages will be increase as tolerated to a maximum recommended dosage of 60 mg per kg per day. Usual dosage is between 1250mg to 2000mg per day
Trial: NCT01342549
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg per day, taken by mouth for 7 days, then 50mg per day
Trial: NCT03283150
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the BIS values to normalize to awake level for the MER.
Trial: NCT01616485
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 sildenafil citrate 50 mg capsules
Trial: NCT03330821
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03330821
Drug: Idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03330821
Drug: Pevonedistat
RxNorm normalized name: Pevonedistat
DrugBank: Pevonedistat (DB11759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03283150
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the BIS values to normalize to awake level for the MER.
Trial: NCT01354704
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enoxaparin 4000 IU 1 injection/day in subcutaneous.
Trial: NCT03125811
Drug: Oral Dissolvable Tablet Zofran (ondansetron)
RxNorm normalized name: ondansetron Oral Tablet [Zofran]
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose 4 mg tablet at 0 minutes.
Trial: NCT02258529
Drug: Idelalisib
RxNorm normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 150 tablets administered orally twice daily
Trial: NCT00539617
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tarceva single agent therapy: 150 mg/day PO
Trial: NCT00539617
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU bolus: 400 mg/m2 IV once every 2 weeks for 16 weeks 5-FU infusion: 2400 mg/m2 IV over 46-48 hours, once every 2 weeks for 16 weeks
Trial: NCT00539617
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 85 mg/m2 IV once every 2 weeks for 16 weeks
Trial: NCT02334488
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Active Comparator
Trial: NCT02334488
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active Comparator
Trial: NCT02334488
Drug: Mycophenolate sodium
RxNorm normalized name: Mycophenolate Sodium
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental Arm
Trial: NCT05918627
Drug: Belumosudil mesylate
RxNorm normalized name: Belumosudil Mesylate
DrugBank: Belumosudil (DB16703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: capsule; Route of administration: oral
Trial: NCT01189292
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 8mg (2ml) of dexamethasone (Mephameson®) administered intravenously preoperatively before thyroid surgery
Trial: NCT02179255
Drug: Human Growth Hormone
RxNorm normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.9 mg (5.7 units) daily injection of Recombinant Human Growth Hormone (HGH) for at least 6 weeks (42 days) continuing into the approximately 14 days of ovulation induction phase of the trial.
Trial: NCT02179255
Drug: Follicle Stimulating Hormone
RxNorm normalized name: follicle stimulating hormone
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: FSH 450 to 600 units per day administered SQ daily dose adjusted based on the patients response starting on day 2 of the 28 day menstrual cycle and continued until Ovulation trigger
Trial: NCT00120055
Drug: Atorvastatin (Lipitor)
RxNorm normalized name: atorvastatin Oral Tablet [Lipitor]
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01318070
Drug: Alogliptin and pioglitazone
RxNorm normalized name: Alogliptin and Pioglitazone Tablets
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alogliptin 12.5mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
Trial: NCT01318070
Drug: Alogliptin and pioglitazone
RxNorm normalized name: Alogliptin and Pioglitazone Tablets
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
Trial: NCT01318070
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
Trial: NCT03772418
Drug: Pomegrante and Ginkgo biloba group
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The extracts of ginkgo biloba and Pomegranate as formulated in topical dosage form will be applied to the 30 aging people who are suffering from wrinkles in the skin male and female. Formulated cream will be applied on two groups, one man (Group Ia)and one woman (Group Ib).
Trial: NCT00364052
Drug: oral Valganciclovir vs oral Ganciclovir
RxNorm normalized name: ganciclovir Oral Capsule
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00693004
Drug: PRX-03140
RxNorm normalized name: PRX-03140
DrugBank: PRX-03140 (DB05596)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00693004
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01616485
Drug: Nitrostat
RxNorm normalized name: Nitrostat
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glyceryl trinitrate tablet, USP 0.4 mg
Trial: NCT00000120
Drug: Silver Nitrate Drops
RxNorm normalized name: Silver Nitrate
DrugBank: Silver nitrate (DB11080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00338910
Drug: Budesonide 2 single doses, Metronidazole multiple-dose
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Budesonide 3 mg single oral dose on Day 1 and Day 9. Metronidazole 750 mg b.i.d. from Day 2 until Day 8, Metronidazole 750 mg once daily (in the morning) on Day 9.
Trial: NCT00392431
Drug: amiodarone
RxNorm normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01533922
Drug: Tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 5 mcg once daily
Trial: NCT01533922
Drug: Olodaterol
RxNorm normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olodaterol 5 mcg once daily
Trial: NCT01533922
Drug: tiotropium + olodaterol
RxNorm normalized name: olodaterol / tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiotropium + olodaterol 5 mcg once daily
Trial: NCT01533922
Drug: Tiotropium + Olodaterol
RxNorm normalized name: olodaterol / tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 2.5 mcg + Olodaterol 5 mcg once daily
Trial: NCT00533858
Drug: lacidipine (4 mg) or losartan (50 mg)
RxNorm normalized name: LACIDIPINE
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lacidipine (4 mg) or losartan (50 mg), both given once daily at the same hour in the morning (approximately at 8 AM) for 12 weeks
Trial: NCT01011972
Drug: XMT-1107
RxNorm normalized name: XMT-2056
DrugBank: XMT-2056 (DB18230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg XMT-1107 administered by I.V. (in the vein) administered over 90 min, once every 21 days : until progression or unacceptable toxicity develops
Trial: NCT00784732
Drug: Mometasone Furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01883648
Drug: Coconut Oil Beverage
RxNorm normalized name: Coconut Oil
DrugBank: Coconut (DB10523)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There are 2 treatment arms: Fuel for Thought™ and placebo, with a treatment allocation of 1:1. After 3 months of treatment in one group, subjects will have a 3-5 day wash-out period before receiving the alternate (opposite) treatment for 3 months.
Trial: NCT00675896
Drug: Quetiapine Fumarate Sustained Release
RxNorm normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/day for the first 2 days and then up to 150mg/day. After two weeks the dose will be doubled up to 300mg at night at the discretion of the investigator
Trial: NCT04292990
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: starting at 30 mg, increasing at a minimum of 3 days intervals by 20 mg, with a maximum dose of 100 mg. Maintenance phase: continuing on dose level established in titration phase.
Trial: NCT01557959
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01557959
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01557959
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04170270
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre endoscopically: all patients will receive 80 mg omeprazole by 30 minute IV infusion.~After performing upper endoscopy (with initial hemostasis), the patient will be randomly allocated into two groups; group A patients will receive oral omeprazole, while group B patients are intended to receive IV omeprazole.~For patients of group A, omeprazole 40 mg will be administrated orally every 12 hours for 72 hours. Regarding group B, continuous infusion of omeprazole will be administrated at a rate of 8 mg/hour, for 72 hours.
Trial: NCT03242252
Drug: Sotagliflozin
RxNorm normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Sotagliflozin 200 mg, tablet, orally once daily.~Route of administration: Oral
Trial: NCT00151788
Drug: Pactimibe sulfate
RxNorm normalized name: SULFATE
DrugBank: Pactimibe (DB12971)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01983124
Drug: Fotemustine + Vemurafenib
RxNorm normalized name: Vemurafenib
DrugBank: Fotemustine (DB04106)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fotemustine 100mg/m2 IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity.~Vemurafenib administered continuous oral dosing 960 mg twice daily or dose administered at time of progression since progression or unacceptable toxicity.
Trial: NCT01842581
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin will be administered per the dose and schedule specified in the arms.
Trial: NCT01842581
Drug: Lactulose
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Laculose will be administered per the schedule specified in the respective arm.
Trial: NCT00993499
Drug: Sirolimus (rapamycin)
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose escalation (19-40 patients): several dose levels + 12 addit. pat. at MTD until progression or undue AEs.
Trial: NCT02192229
Drug: 50.000 IU vitamin D3 (Biodal 50,000 IU)
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01020708
Drug: mesalamine
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4.0g mesalamine rectal suspension, rectally administered enema, 60ml volume, 4.0g mesalamine, once daily
Trial: NCT01496105
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01496105
Drug: saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00012363
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1,000mg/m2, IV over 30 min, days 1 \& 8, q 21 days
Trial: NCT00012363
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg/m2, IV over 90 min, days 1 \& 8, q 21days
Trial: NCT01287195
Drug: Oral OKT3
RxNorm normalized name: Humanized OKT3
DrugBank: Teplizumab (DB06606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg or 2 mg Oral OKT3 will be given orally to participants once daily for 30 days
Trial: NCT01287195
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg Omeprazole will be given orally to participants once daily for 30 days
Trial: NCT04621500
Drug: cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled subjects will supplement with vitamin D3 at 4,000 IU daily for one year
Trial: NCT04049110
Drug: Forxiga 10mg
RxNorm normalized name: Farxiga
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin 10mg per 24 hours, oral, for 7 consecutive days
Trial: NCT00334282
Drug: Pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral pazopanib tablet 800 mg once daily continuously
Trial: NCT03759964
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1g of Ferric carboxymaltose diluted in 100 mL of IV isotonic serum saline at day 1 following surgery
Trial: NCT01281228
Drug: exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests.
Trial: NCT01281228
Drug: exenatide + exendin (9-39)
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests. Exendin 9-39 will be infused intravenously at doses of 600 pM/kg • min.
Trial: NCT00162266
Drug: Abatacept (BMS-188667)
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV, 10 mg/Kg, monthly, for the duration of the trial
Trial: NCT00162266
Drug: Abatacept (BMS-188667)
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous (IV) infusion, 2 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
Trial: NCT00162266
Drug: Abatacept (BMS-188667)
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous (IV) infusion, 10 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months